Transcription of Reference ID: 3979266 - Erelzi
{{id}} {{{paragraph}}}
Example: bankruptcy
Reference ID: 3979266 - Erelzi
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ERELZITM safely and effectively. See full prescribing information for Erelzi . Erelzi (etanercept-szzs) injection, for subcutaneous use Initial Approval: 2016 Erelzi (etanercept-szzs) is biosimilar to ENBREL (etanercept).* WARNINGS: SERIOUS INFECTIONS AND MALIGNANCIES See full prescribing information for complete boxed warning. SERIOUS INFECTIONS Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens.
Preparation of ERELZI : ERELZI is intended for use under the guidance and supervision of a physician. Patients may self-inject when deemed appropriate and if they receive medical follow-up, as necessary.
Loading..
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: